Table 1. Somatic mutations of PIK3CA in cancer types reported since 10/2005.
Cancer | % PIK3CA mutationa | Sample source (primary tissue vs cancer cell line) | Exon mutated | Functional domain | Reference |
---|---|---|---|---|---|
Liver | 35.6 (26/73) | Primary | 9 and 20 | Helical and kinase | Lee et al (2004) |
Total liver 36% (26/73) | |||||
Breast | 33.3 (4/12) | Cell lines | 9 and 20 | Helical and kinase | Bachman et al (2004) |
Breast | 21.4 (9/42) | Primary | 1, 9 and 20 | p85, helical and kinase | Bachman et al (2004) |
Breast | 18.1 (13/72) | Primary | 9 and 20 | Helical and kinase | Levine et al (2005) |
Breast | 40.0 (28/70) | Primary | 6, 7, 9 and 20 | C2, helical and kinase | Campbell et al (2004) |
Breast | 20.7 (19/92) | Primary | 9 and 20 | Helical and kinase | Wu et al (2005a) |
Breast | 8.3 (1/12) | Primary | 20 | kinase | Samuels et al (2004) |
Breast | 33.3 (5/15) | Cell lines | 9 and 20 | Helical and kinase | Wu et al (2005a) |
Breast | 26.9 (25/93) | Primary | 9 and 20 | Helical and kinase | Lee et al (2004) |
Breast | 28.0 (14/50) | Cell lines | 1, 9 and 20 | p85, helical and kinase | Saal et al (2005) |
Breast | 26.4 (77/292) | Primary | 1, 4, 7, 9, 13, 18, 20 | p85, C2, helical and kinase | Saal et al (2005) |
Total breast 26% (195/750) | |||||
Colon | 31.6 (74/234) | Primary | 1, 2, 4, 7, 9, 18 and 20 | P85, C2, helical and Kinase | Samuels et al (2004) |
Colon | 13.6 (14/103) | Primary | 9 and 20 | Helical and kinase | Velho et al (2005) |
Colon | 18.8 (6/32) | Primary | 9 and 20 | Helical and kinase | Campbell et al (2004) |
Total colon 25% (94/369) | |||||
Ovarian | 12.1 (24/198) | Primary | 9 and 20 | Helical and kinase | Levine et al (2005) |
Ovarian | 6.0 (11/182) | Primary | 9 and 20 | Helical and kinase | Campbell et al (2004) |
Total ovarian 9% (35/380) | |||||
Gastric | 25.0 (3/12) | Primary | 18 and 20 | Kinase | Samuels et al (2004) |
Gastric | 10.6 (5/47) | Primary | 9 and 20 | Helical and kinase | Velho et al (2005) |
Gastric | 6.5 (12/185) | Primary | 9 and 20 | Helical and kinase | Lee et al (2004) |
Gastric | 4.3 (4/94) | Primary | 9 and 20 | Helical and kinase | Li et al (2005) |
Total gastric 7% (24/338) | |||||
Brain | 26.7 (4/15) | Primary | 4, 5 and 13 | C2 and helical | Samuels et al (2004) |
Brain | 4.6 (13/285) | Primary | 9 and 20 | Helical and kinase | Broderick et al (2004) |
Total brain 6% (17/300) | |||||
Lung | 1.3 (3/229) | Primary | 9 and 20 | Helical and kinase | Lee et al (2004) |
Lung | 4.2 (1/24) | Primary | 9 | Helical | Samuels et al (2004) |
Total lung 2% (4/253) | |||||
Leukaemia | 1.1 (1/88) | Primary | 9 | Helical | Lee et al (2004) |
Total leukaemia 1% (1/88) | |||||
Total cancers reported 15% (382/2551) |
The majority of PIK3CA documented mutations being somatic missense mutations, this table does not include other genetic changes (i.e. gene amplifications, deletions, insertions, etc.).